Cite
HARVARD Citation
D'Amico, R. et al. (n.d.). LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials. Open forum infectious diseases. pp. S847-S848. [Online].